RE:RE:Did CXR Overpay for Amdipharm Mercury...?It seems CXR management did the math and decided that AMCo deal will pay for itself in relatively short time and that there will be synergies between the two previous companies that generates more revenues to the new combination over time. AMCo has a much wider marketing platform worldwide that benefits new product distributions that CXR previously could not acquire. There was an interview from MT about that recently. They may outperform their revenue forecasts with new developments in the healthcare competition. I am sure others can explain all this much better.
pineapple1 wrote: They thought it prudent to lever themselves to the tune of 6x debt /ebitda for mid to high single digit yoy growth.